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Abstract
Background: Many middle-income countries are scaling up health insurance schemes to provide financial protection
and access to affordable medicines to poor and uninsured populations. Although there is a wealth of evidence on
how high income countries with mature insurance schemes manage cost-effective use of medicines, there is limited
evidence on the strategies used in middle-income countries. This paper compares the medicines management
strategies that four insurance schemes in middle-income countries use to improve access and cost-effective use of
medicines among beneficiaries.
Methods: We compare key strategies promoting cost-effective medicines use in the New Rural Cooperative Medical
Scheme (NCMS) in China, National Health Insurance Scheme in Ghana, Jamkesmas in Indonesia and Seguro Popular in
Mexico. Through the peer-reviewed and grey literature as of late 2013, we identified strategies that met our inclusion
criteria as well as any evidence showing if, and/or how, these strategies affected medicines management. Stakeholders
involved and affected by medicines coverage policies in these insurance schemes were asked to provide relevant
documents describing the medicines related aspects of these insurance programs. We also asked them specifically to
identify publications discussing the unintended consequences of the strategies implemented.
Results: Use of formularies, bulk procurement, standard treatment guidelines and separation of prescribing and
dispensing were present in all four schemes. Also, increased transparency through publication of tender agreements
and procurement prices was introduced in all four. Common strategies shared by three out of four schemes were
medicine price negotiation or rebates, generic reference pricing, fixed salaries for prescribers, accredited preferred
provider network, disease management programs, and monitoring of medicines purchases. Cost-sharing and payment
for performance was rarely used. There was a lack of performance monitoring strategies in all schemes.
Conclusions: Most of the strategies used in the insurance schemes focus on containing expenditure growth, including
budget caps on pharmaceutical expenditures (Mexico) and ceiling prices on medicines (all four countries). There were
few strategies targeting quality improvement as healthcare providers are mostly paid through fixed salaries, irrespective
of the quality of their prescribing or the health outcomes actually achieved. Monitoring healthcare system performance
has received little attention.
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Background
Over the last decade international agencies and individual
countries have shown commitment to promote universal
health coverage (UHC), defined as: “[…] ensuring that all
people have access to needed promotive, preventive, cura-
tive and rehabilitative health services, of sufficient quality
to be effective, while also ensuring that people do not suf-
fer financial hardship when paying for these services” [1].
The World Health Organization (WHO) defines a
series of necessary conditions to achieve UHC, one of
which relates to medicines - “Access to essential medi-
cines and technologies to diagnose and treat medical
problems.” Various authors have described in more de-
tail how to define access and how to measure it [2, 3].
Nonetheless, how to balance medicines access, afford-
ability, quality and sustainability of supply, has played a
relatively minor role in discussions regarding UHC and
the necessary conditions needed to achieve it [4]. Medi-
cines management is critical to successful implementa-
tion of UHC but, until recently, few studies exist guiding
policy development and implementation in low and
middle-income countries.
Accordingly, we employ a case-based approach to study
what strategies payers use to promote cost-effective use of
medicines. We have chosen four insurance schemes in
Mexico, China, Ghana and Indonesia, which provide
coverage for poor and/or underserved populations. We
compare the medicines management strategies to pro-
mote cost-effective use of medicines in these insurance
schemes and discuss challenges in their implementation.
Methods
Selection of the countries
We chose four countries (China, Indonesia, Ghana and
Mexico) which (1) are at different stages of development
with regard to UHC of their population; (2) have different
funding arrangements (e.g. social health insurance (SHI)
or tax-based systems), and (3) are from different geo-
graphical regions. In addition, we also considered country
income level and whether the health service providers are
public or private.
Literature review and stakeholder interviews
We carried out a desk review of relevant peer-reviewed
and grey literature related to UHC and medicines pub-
lished between 2000 and 2013 for each of the four coun-
tries. To complement our review we conducted interviews
with stakeholders (3 in China; 4 in Ghana, 1 each in
Indonesia and Mexico) involved in developing medicines
coverage policies or affected by these policies. We sought
the perception of these stakeholders regarding relevant
publications as well as administrative documents describ-
ing the medicines- related aspects of the health benefit or
insurance programs. We also asked them specifically to
identify publications discussing the unintended conse-
quences of medicines coverage and pharmaceutical man-
agement policies in place.
Conceptual framework for analysis
Analytically, the medicines and finance policies used to
balance access, affordability, quality and sustainability
were divided into the following five broad categories [5]:
(1) selection, (2) procurement, (3) contracting, (4)
utilization management, and (5) monitoring member
satisfaction, and purchasing and prescribing patterns.
For each of these broad categories, the public and pri-
vate sectors have often-times competing interests with
regard to UHC [4]. These interests are: (1) keeping costs
affordable, (2) ensuring availability of quality generic and
innovator products, (3) improving equitable access, and
(4) ensuring appropriate use.
Results
Brief summary of scaling up health insurance coverage in
each country studied
Table 1 describes the countries included and their
respective characteristics as of 2014. They represent a
range of insurance coverage from 39% in Ghana to ap-
proximately 100% for Mexico and China. Two countries
have UHC with only government revenue funding
(Indonesia, Mexico), two a mix of government revenues
and beneficiary contribution (Ghana, China). Each coun-
try is from a different WHO Region. Two countries are
lower-middle (Indonesia, Ghana) and two are upper-
middle income countries (Mexico, China). An overview of
the demographic, health and health care related indicators
of the four countries chosen can be found in Appendix.
China
In China, three major health insurance programs cover
specific groups: rural residents under the New Rural
Cooperative Medical Scheme (NCMS), urban employees
under the Urban Employees Basic Medical Insurance (UE-
BMI), and unemployed urban residents under the Urban
Residents Basic Medical Insurance (UR-BMI). We note
that in early 2016, China announced the decision to merge
the UR-BMI and NCMS schemes [6]. There will be unified
coverage, a fund pooling mechanism, a benefits package
and reimbursement rates, a basic medical insurance drug
list, unified selection of health providers, and fund manage-
ment. For the purpose of this retrospective study, only the
NCMS will be analyzed as no evaluation has been made of
the combined UR-BMI and NCMS schemes. Various ex-
periments are also taking place at lower levels, giving the
entire Chinese insurance system a very dynamic nature.
The NCMS incorporates voluntary enrollment and cover-
age of catastrophic illnesses. Apart from these two require-
ments, the design and implementation of the program is
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left to local governments. An extensive survey in Western
and Central China found the most common model of
NCMS combines a medical savings account (MSA) and
high-deductible catastrophic insurance for inpatient ser-
vices. Eighty percent of the 10 RMB premium (about 1.5
USD as of this writing), is put into an MSA to pay for
outpatient visits and can be shared among household
members. The government’s 20 RMB subsidy plus the
remaining 2 RMB premium are pooled to cover inpatient
hospital expenses above a certain deductible. The amount
of the deductible varies by locale, with the majority of them
above 400 RMB. Besides the deductible, patients still have
to pay 40–60% of covered inpatient expenses. The benefit
package also caps the benefit payment at 10,000–20,000
RMB. NCMS risk-pooling is at the county level, not the
village level.
Indonesia
In 2005, the Askeskin program provided basic health
coverage and medicines to the poor. This health insurance
program was later expanded to include the near-poor in
2007 and renamed as Jamkesmas. The Jamkesmas program
in 2012 had over 76 million beneficiaries – a third of the
national population – and was the largest health insurance
scheme in Indonesia [7]. Two other social health insurance
schemes also existed in Indonesia: Askes was targeted to
civil servants and had 17 million beneficiaries while
Jamsostek enrolled 5 million employees in the private
sector [7]. Combined, the three social health insurance
programs covered 40% of the Indonesian population in
2012. However, the analysis in this study only looked at the
Jamkesmas program from 2012–2013 and its medicines re-
lated benefits. We note that the Indonesian government
enacted the Badan Penylenggara Jaminan Sosial (BPJS)
law (Law No. 24/2011) in 2011 which was intended
to unify all social health insurance programs under one
not-for-profit administrator in 2014. The Indonesian
government rolled out the Jaminan Kesehatan National
(JKN) program on January 1, 2014, with the ambition to
achieve national UHC by January 2019 [8].
Ghana
In 2003, the National Health Insurance Authority (NHIA)
was established as the regulator and the implementer of
all health insurance schemes in the country (National
Health Insurance Scheme (NHIS)). The NHIS is primarily
financed by a 2.5 percentage top up of the Value Added
Tax (National Health Insurance Levy) and a 2.5% levy of
social security contributions made by formal sector em-
ployees (involuntary payroll deductions), and premiums
paid by informal sector workers [9]. Both public and pri-
vate health facilities are accredited to provide services
under coverage by the NHIS. More than 50% of all pa-
tients, whether using the NHIS or not, seek care from the
private sector [10]. These private institutions include for-
profit standalone pharmacies and licensed chemical
sellers, for profit hospitals and clinics and not-for-profit
health providers (mission hospitals). Mission health facili-
ties which account for a substantial proportion of district
hospitals in the country are usually described as private
not for profit but their health workers are on government
employee payroll and they also benefit from government
programs meant for the public sector. In total, govern-
ment support to overall expenditure of mission health fa-
cilities budget is 34–35%; the remaining is internally
generated. In terms of service delivery mission institutions
provide 30% of inpatient care and 20% of outpatient care
(personal communication from key informant). Apart
from the NHIS there are a small number of private in-
surers which also offer insurance packages with medicines
benefits to well-to-do clients and are outside the scope of
this study which will focus on NHIS.
Table 1 Countries selected as case studies and the characteristics as of 2014
Country Development stage of UHCa %
population covered in the
entire countrya
Funding arrangement
(year of inception)b
Geographical region
(WHO region)
Country income
level
Provider mixb
China 90% NRCMS (2003): Premiums and
federal and local government
subsidies
URBMI (2007): Premiums and
government subsidies
WPR UMIC NRCMS: Largely private
contractors
URBMI: Largely public
Indonesia 40–63% JAMKESMAS (2004):
Government revenues
SEAR LMIC Jamkesmas: Nearly
exclusively public
Ghana 39% NHIS (2004): Social Health
Insurance
AFR LMIC NHIS: Mixed public/private
providers
Mexico 80–100% SP (2003): Premiums and taxes AMR UMIC SP: Nearly exclusively public
aThe percentage of the population covered varies by data source and method of estimating coverage; hence, we report for some countries a range. Percentage
coverage is based on most recent reporting or 2014, whichever is later
bThis information refers to the reform program that specifically targets the poor population: NRCMS New Rural Coorperative Medical Scheme, URBMI Urban
Residence Basic Medical Insurance, MoHME Ministry of Health and Medical Education, NHIS National Health Insurance Scheme, RHI Rural Health Insurance,
SP Seguro Popular
Region: WPR Western Pacific Region, SEAR South-east Asian Region, AFR African Region, AMR Region of the Americas, EMR Eastern Mediterranean Region
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Mexico
In 2000 around 50% of the population did not have
health insurance, mostly those working in the informal
sector or the self-employed [11]. In the past, the entitle-
ment of health insurance had been defined by employ-
ment status with those in formal employment and their
dependents covered by social security [12]. With the cre-
ation of the national health insurance program called
Seguro Popular in 2003 the Mexican government initi-
ated to scale up UHC with the aim to reach 100% popu-
lation coverage by 2010 (which was later extended to
2011). Affiliation was targeted towards the population
previously not covered by social insurance. Official
government sources declared 100% coverage in 2012
[13]. Seguro Popular seeks to provide health service
coverage, through voluntary, public insurance for per-
sons that are not affiliated to any social security institu-
tion. In 2014 it provided coverage for 275 medical
interventions, described in the Universal Health Service
Catalogue. Seguro Popular is operated at national level
by the National Commission of Social Protection in
Health (CNPSS). At State level the State Seguro Popular
Fund Holders (REPSS) are responsible to manage funds
and purchase care. As the health system is decentralized,
the national policies are implemented in a heteroge-
neous manner throughout the states [14].
Strategies to promote cost-effective medicines use
For the four programs studied –NCMS, NHIS, Jamkesmas
and Seguro Popular- strategies to select medicines were
well documented in the literature. In contrast, purchasing,
contracting and utilization were less well documented.
Table 2 presents a comparison between the four programs.
The following strategies to promote cost-effective
medicines use were common to all the four insurance
programs (in bold in Table 2):
 use of formularies (at various levels in the healthcare
system),
 bulk procurement,
 use of standard treatment guidelines and
 separation of prescribing and dispensing.
Formularies in the four cases were based on national
essential medicines lists but each program adapting or
modifying it for its specific needs. For instance, for the
NCMS formularies, part of the medicines are selected
from the national EML which in 2012 contained 520
Table 2 Overview of strategies used to promote cost-effective use of medicines in the four medicines benefit programs
Type of strategies Strategies Medicines NCMS
(China)
National Health
Insurance (Ghana)
Jamkesmas
(Indonesia)
Seguro Popular
(Mexico)
Selection Formulary ✓ ✓ ✓ ✓
Cost sharing for medicines
included in the formulary
✓ ✗ ✗ ✗
Generic substitution ✗ ✓ ✗ ✗
Procurement Medicines prices negotiation
or rebates
✓ ✗c ✓ (✓)
Bulk procurement ✓ ✓a ✓ ✓
Generic reference pricing ✗ ✓ ✗a ✓
Contracting Fee for service for prescribers ✓
Fixed salary for prescribersa ✓ ✓a ✓
Fixed reimbursement rates
for medicines
✓ ✓ ✗ ✗
Preferred provider network
(accreditation)
✗ ✓ ✓ ✓
Utilization Standard treatment guidelines (✓) ✓ ✓ ✓
Payment for performance (✓) ✗ ✗ ✗
Separation of prescribing
and dispensing
✓ ✓ ✓ ✓
Disease management programs ✓ No info ✓ ✓
Monitoring and evaluation User satisfaction monitoring ✗ ✗ ✗ ✓
Medicines purchasing
monitoring
✓b ✓ ✓
Prescription monitoring ✗ ✗ ✗ ✗
a = in the public sector; () = Limited use; b = information not publically available; c = healthcare facilities do their own negotiation with suppliers; italics = strategies
common to all the four insurance programs
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medicines, 317 Western and 203 Traditional. Since each
province has their own EML (the National EML plus a
provincial supplementary list), some medicines are taken
from the provincial supplementary list. Programs made a
distinction between medicines used at lower levels of care
(e.g. primary care) versus those that should be available at
high levels of care (second or tertiary care).
For all four programs the bulk procurement was done
at regional level or national level (e.g. state or province).
Systems to increase transparency of public procurement
prices, volumes and bidding process were recently intro-
duced in all of them [15–17]. Standard treatment guide-
lines had been developed in all four of them [18–21].
However, the extent to which they are implemented into
clinical practice and linked to the selection of medicines
for inclusion in the formulary varies. For instance, little
information was found on the selection criteria of medi-
cines included into the provincial formularies of NCMS
and the establishment of evidence-based guidelines in
contrast to experience-based care is a challenge in many
settings [18]. In contrast, the formulary of Seguro Popular
refers to clinical guidelines [22].
Furthermore, medicine price negotiation or rebates,
generic reference pricing, fixed salaries for prescribers,
accredited preferred provider network, disease manage-
ment programs and monitoring of medicines purchases
were implemented by three of the four schemes.
In Ghana, payment structures for public sector pre-
scribers and dispensers is based on a policy which places
all public service employees on a single vertical salary
structure [23]. Thus prescribers are paid fixed salaries,
irrespective of the quality and volume of services ren-
dered. In Indonesia public health workers, including
government physicians and pharmacists, receive a fixed
salary independent of productivity or capitation [24]. In
Mexico, prescribers in the public sector that provide ser-
vices for Seguro Popular beneficiaries are paid by fixed
salaries and do not receive any payment related to ser-
vices provided (no financial incentives nor disincentives).
Many physicians working in public health units also
have their private consultancy offices [25].
In China, payment was linked to volume and type of
dispensing services [15, 26, 27]. Whereas Indonesia [7]
and Mexico (information provided by key informant)
had fixed salaries for those filling prescriptions in the
public sector, dispensing charges in China were included
in the product reimbursements [27, 28]. There were no
dispensing fees in Ghana [29].
There was a lack of information on payment for per-
formance, monitoring user satisfaction and prescription
monitoring.
Jamkesmas and Seguro Popular share many common
strategies. In the case of Jamkesmas in Indonesia [7] and
Seguro Popular in Mexico most providers (prescribers
and dispensers) are located in public clinics that operate
under the provincial or state directed Ministry of Health
[30]. Dispensing outlets and pharmacies are within the
clinics. The decentralization of the health system in
Indonesia and in Mexico results in variations in the
pharmaceutical policy strategies implemented by provin-
cial Jamkesmas administration [31] and state Seguro
Popular Fundholders [32]. One important way in which
Jamkesmas differs is in the variation in medicines
procurement prices among provinces [33]. In Seguro
Popular states are mandated to procure at a price that
does not exceed a certain amount [34]. In addition to
public and private hospitals and clinics, the NHIS in
Ghana contracts private standalone pharmacies, and li-
censed chemical sellers to dispense medicines [29].
The rapid changes and large regional differences in
the NCMS in China have made it difficult to describe
the current general strategies to promote access and
utilization via this insurance scheme. Users have to pay
a deductible before the schemes start covering medi-
cines [28, 35]. The coverage has a cap after a maximum
insurance payment has been reached in a given time
frame [28, 35, 36].
Reported impact of strategies of promote cost-effective use
of medicines
With regard to China, in terms of the consequences of
financing strategies on availability, access, and use of
medicines, as well as on household and health system af-
fordability, early cross-sectional appraisals of the health re-
forms found lower medicines prices in primary care
facilities [37]. However, impacts of the health reform on
generally low availability [38], total number of prescriptions
[39, 40] or less-than-appropriate use [41] was not clear.
In Ghana, expenditures on medicines had increased
after the introduction of NHIS [42, 43]. Supplier induced
demand for medicines in private hospitals have also been
documented [44]. Another study has shown that enroll-
ment patterns did not match well with the medicines
utilization changes and the authors have questioned
whether the increased spending has improved equity in
access and appropriate use [45].
In Ghana and Indonesia, key informants considered
the claims-processing systems inefficient, which is
often paper-based rather than electronic, and require
resource-consuming reviews. Inefficient claims-review
systems can lead to delays in payments to facilities,
shortages of facility funds to purchase medicines, and
medicines stock-outs [9].
In Mexico, no decrease in household expenditure on
medicines was found 10 months after the introduction of
the insurance scheme [46] or no statistically significant
difference in household expenditure was found in com-
parison to households not insured by Seguro Popular [47].
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Discussion
This study compares strategies to promote cost-effective
use of medicines in insurance schemes targeting poor
populations in middle-income countries. Whereas medi-
cines policies to manage medicines in insurance schemes
in high-income countries are well documented there is a
lack of evidence from low- and middle-income countries
[48, 49]. Transferability of evidence from high-income
settings is limited and the creation of knowledge from
low- and middle-income countries is relevant particu-
larly given that many of them are making strides to
move towards UHC. Our study contributes to the cre-
ation of evidence by analyzing four schemes operating in
middle-income countries as case studies.
The results show that the identified country strategies
aim to contain expenditure growth through budget caps
on pharmaceutical expenditures (Mexico) and medicines
price limits (all four countries). Moreover, all four
schemes use strategies for cost containment through se-
lection, bulk procurement and standard treatment guide-
lines. Price negotiation and rebates are also very
common (China, Indonesia and Mexico). All these
policies and practices including tendering are also com-
monly implemented in high-income settings [49].
However, the results show that there are a series of
challenges in policies that aim to improve performance
e.g. providers are mostly paid through fixed salaries, irre-
spective of the quality of their prescribing efficiency or
the health outcomes actually achieved. On one hand,
fixed salaries can protect against financial incentives to
over-prescribe certain medicines for which prescribers
receive a bonus [50]. On the other side, lack of incen-
tives reinforcing good performance or sanctions to im-
pede low quality can result in inadequate prescribing
[51]. Policies to improve quality improvement are often
more challenging to implement effectively; for instance,
payment for performance requires advanced information
systems to collect data on provider performance; the
availability of such systems is usually limited in middle-
income countries [52].
Three of the four schemes do not have cost sharing
systems in place, in other words, beneficiaries receive
the medicines included in the benefit package free of
any co-payment. This protected individuals from finan-
cial hardship and out-of-pocket expenditure. An excep-
tion was China where there are many different kinds of
cost-sharing schemes [53]. It is important to note that
there is some evidence of cost-sharing in the Chinese
NCMS reducing financial risk of the beneficiaries.
Of the four countries, only Ghana has generic substi-
tution, an advantage in containing costs. Whether it is
useful to introduce a generic substitution policy for cost
containment depends very much on the context, such
as architecture of the pharmaceutical supply and
reimbursement system in place. Generic substitution
policies are uncommon in systems where the same in-
stitution procures, distributes, and dispenses medi-
cines. By design, these schemes procure generic
medicines whenever available; originator or brand
medicines are not available at the point of dispensing.
Finally, there was little information on any systematic
monitoring and publishing performance metrics of
medicines prescribing and expenditure by these insur-
ance schemes. For instance, it was unclear how perform-
ance of prescribers was monitored, used for feedback or
to inform future interventions to promote more appro-
priate use of medicines. The absence of information is
not sufficient to say that schemes do not carry out these
activities. In case these insurance schemes lack monitoring
systems and performance metrics it will be challenging to
implement the aforementioned policies efficiently, track
their impact and adjust them if necessary.
The interpretation of the study results should take into
consideration the following limitations: the analysis of
strategies did not include an assessment of how well
they were implemented. In addition, there is limited evi-
dence to evaluate their impact on cost-effective use and
access. Furthermore, rapid changes in strategies imple-
mented by each of these insurance schemes make it dif-
ficult to keep track and accurately report the status quo.
However, this is a limitation that applies to other policy
analyses due to the nature of systems that are constantly
changing. For certain types of strategies, it was easier to
obtain information such as a selection of medicines (e.g.
for instance, formularies were publiclly available). In
contrast, strategies on procurement and reimbursement
of providers were much harder to identify and report on.
Hence, underreporting on these strategies is possible.
However, we asked stakeholders specifically to provide
us with information on documentation gaps to avoid
publication bias.
Conclusions
Moving towards UHC requires countries to promote
efficient use of financial resources in all areas of health
services including medicines. Insurance schemes in
middle-income countries have used a variety of strat-
egies to ensure cost-effective use of medicines; there is
no single strategy that will be suitable for all middle-
income countries. There is an opportunity for insurance
schemes to expand the type of strategies from cost-
containment strategies towards those that incentivize
quality use of medicines. To that end, we have identified
a number of policy gaps that insurance schemes should
address, in particular performance based payments and
monitoring and performance metrics. Insurance schemes
should pay closer attention to these policies.
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Table 3 Country profiles of four countries included in the case studies (2010)
Indonesia China Ghana Mexico
Demographics
Number of inhabitants in 1,000 s 242,326 1,355,243 24,966 114.8
Life expectancy in years 2011
Male 68 74 62 72
Female 71 77 65 78
Population distribution
Median age 28 35 21 27
% population under 15 27 19 38 29
% population over 60 8 13 6 9
Economics and health systems financing
Income group Lower middle Upper middle Lower middle Upper middle
% total health expenditure of GDP 2.8 5.0 5.2 6.3
% public expenditure of THE 36.1 54.3 58.2 49.0
% pharmaceutical expenditure of THE 1/3
per capita total expenditure on health (PPP int. $) 123 373 85 962
Health indicators
Age-standardized mortality rates by NCD (per 100,000 population) 2008 647 604 711 493
Prevalence of raised fasting blood glucose among adults aged ≥ 25 years] (%) 2008
Male 6.6 9.6 9.9 13.2
Female 7.1 9.4 10.3 14.9
Prevalence of raised blood pressure among adults aged ≥ 25 years 2008
Male 32.5 29.8 32.7 27.4
Female 29.3 25.6 31.6 21.5
Adults aged ≥20 years who are obese, 2008
Male 2.5 4.6 4.4 26.7
Female 6.9 6.5 11.7 38.4
Prevalence of smoking any tobacco product among adults aged ≥15 years (%), 2009
Male 61 51 11 24
Female 5 2 3 8
Alcohol consumption Among adults aged ≥15 years
(litres of pure alcohol per person per year) 2008
0.6 5.6 3.1 8.6
Maternal mortality, 2011
Deaths per 100 000 live births
220 37 350 50
Under five mortality, 2011
Total number of such deaths per 1000 live births
151 15 78 16
Vaccination measles Immunization coverage among
1-year-olds (%) 2011
89 99 91 98
HIV prevalence
HIV infections per 100 000 population per year
155 … 907 156
Health systems capacity
Number of physicians per 10,000 inhabitants 2.0 14.6 0.9 19.6
Hospital beds (per 10,000 population) 6 39 9 17
Formal population coverage (% covered by insurance or
tax-based arrangements)
40–60% 75–100%
Year of implementation UHC 2005 2003
Appendix
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